AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials
Group staging classification.
(6.) Sterling TR, Scott NA, Miro JM, et al.; Tuberculosis Trials Consortium; AIDS Clinical Trials
Group for the PREVENT TB Trial.
(ACTG, AIDS Clinical Trials
Group; SHCS, Swiss HIV Cohort Study; images from Servier PowerPoint Image Bank http://www.servier.com/Powerpoint-image-bank.) Impact of poor adherence on mortality Model of HIV disease Improving adherence from 50% to progression (20) 80% adds up to 2 life-years Improving adherence from 80% to 100% adds up to 4.8 life-years 3ISO in SHCS starting ART Missing >2 doses in past 4 weeks 2003-2013 (18) raises death risk 2.89-fold IN MSM missing >2 doses in past 4 weeks raises death risk 4.87-fold 643 ACTG participants enrolled Time-updated nonadherence raises 1997-1999 (21) AIDS progression/death risk 1.84-fold
(36) Many low-risk patients in accordance with the ACTG (AIDS Clinical Trials
Group Oncology Committee) classification present tumor regression with HAART alone.
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials
group (ACTG) A5073, a 48-week randomized controlled trial.
Kaposi'ssarcomain theacquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria; AIDS Clinical Trials
Group Oncology Committee.
Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trials
. Current HIV/AIDS Report 2010;7:194-200.
The findings were unveiled by the International Maternal Pediatric Adolescent AIDS Clinical Trials
Group (IMPAACT) during the 2011 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
It was also the site of ongoing HIV/ AIDS clinical trials
and Lyme disease research, funded by Jemsek.
Tripathy, Scientist F, National AIDS Research Institute (NARI), Pune, participated in the Adult AIDS Clinical Trials
Group Meeting at Washington, D.C.
Sharon Nachman on behalf of the Pediatric AIDS Clinical Trials
Research (Pediatric AIDS Clinical Trials
Group protocol P1008) has demonstrated that once the immune system is restored to CD4+ percentages reflecting asymptomatic disease, prophylaxis for opportunistic infections can be safely withdrawn in children over 2 years (Nachman et al., 2005).